<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04262466</url>
  </required_header>
  <id_info>
    <org_study_id>IMC-F106C-101</org_study_id>
    <nct_id>NCT04262466</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors</brief_title>
  <official_title>Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunocore Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunocore Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC Â®) designed for the
      treatment of cancers positive for the tumor-associated antigen PRAME. This is a
      first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult
      patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The IMC-F106C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable
      tumors which include select Advanced Solid Tumors and will be conducted in two phases.

        1. Phase 1: To identify the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 dose
           (RP2D) of IMC-F106C as a single agent (Arm A) and administered in combination with
           Checkpoint Inhibitors (Arm B).

        2. Phase 2: To assess the preliminary anti-tumor activity of IMC-F106C in up to 4
           indications, as a single agent administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential Assignment from Arm A to B: B can be opened after at least 3 cohorts have been enrolled in Arm A</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Incidence of Dose-limiting toxicity (DLT)s</measure>
    <time_frame>From first dose to DLT period (28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: incidence and severity of adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: changes in laboratory parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) laboratory abnormalities of anemia, activated partial thromboplastin time prolonged, alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, hemoglobin increased, INR increased, lipase increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, serum amylase increased, white blood cell decreased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, chronic kidney disease, proteinuria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: changes in vital signs</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) vital sign abnormalities of fever, hypothermia, weight gain, weight loss, hypoxia, hypertension</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: changes in electrocardiogram parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>QTcF interval absolute values and changes from baseline will be summarized</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: dose interruptions, reductions, and discontinuations</measure>
    <time_frame>from first dose through last dose (anticipated for up to 12 months)</time_frame>
    <description>Number of participants with, and rate of, dose interruption, dose reduction, permanent discontinuation of study treatment Number of participants with, and rate of, dose interruption, dose reduction, permanent discontinuation of study treatment due to adverse event Number of participants with, and rate of, dose interruption, dose reduction, permanent discontinuation of study treatment due to treatment-related adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Best overall response (BOR)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Best Overall Response (BOR)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>approximately 3 weeks (IMC-F106C AUC will be assessed for ~3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>approximately 3 weeks (IMC-F106C Cmax will be assessed for ~3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>approximately 3 weeks (IMC-F106C Tmax will be assessed for ~3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The elimination half-life (t1/2)</measure>
    <time_frame>approximately 3 weeks (IMC-F106C t1/2 will be assessed for ~ 3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-IMC-F106C antibody formation</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lymphocyte counts over time</measure>
    <time_frame>approximately 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum cytokines over time</measure>
    <time_frame>approximately 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Select Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>IMC-F106C - Arm A - Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMC-F106C - Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy dose expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMC-F106C</intervention_name>
    <description>Weekly IV Infusions</description>
    <arm_group_label>IMC-F106C - Arm A - Phase 1</arm_group_label>
    <arm_group_label>IMC-F106C - Phase 2</arm_group_label>
    <arm_group_label>IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-PD(L)1</intervention_name>
    <description>Every 3 weeks</description>
    <arm_group_label>IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ECOG PS 0 or 1

          2. HLA-A*02:01 positive

          3. PRAME positive tumor

          4. Relapsed from, refractory to, or intolerant of standard therapy

          5. If applicable, must agree to use highly effective contraception

          6. Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions listed in the Informed Consent (ICF) and protocol

        Exclusion Criteria:

          1. Symptomatic or untreated central nervous system metastasis

          2. Recent bowel obstruction

          3. Ascites requiring recurrent paracentesis

          4. Significant immune-mediated adverse event with prior immunotherapy (patients in
             combination treatment)

          5. Inadequate washout from prior anticancer therapy

          6. Significant ongoing toxicity from prior anticancer treatment

          7. Out-of-range laboratory values

          8. Clinically significant cardiac disease

          9. Ongoing requirement for immunosuppressive treatment

         10. Prior solid organ or bone marrow transplant

         11. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

         12. Known history of human immunodeficiency virus (HIV)

         13. Significant secondary malignancy

         14. Hypersensitivity to study drug or excipients

         15. Antibiotics, vaccines or surgery within 2-4 weeks prior to the first dose of study
             intervention

         16. Pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaad Abdullah, MD, FACP</last_name>
    <role>Study Director</role>
    <affiliation>Immunocore Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaad Abdullah, MD, FACP</last_name>
    <phone>484-534-5261</phone>
    <email>clinicaltrials@immunocore.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Menendez</last_name>
      <email>rmenendez@theangelesclinic.org</email>
    </contact>
    <investigator>
      <last_name>Omid Hamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehenvise Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffany Lim</last_name>
      <email>sllim@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Frances Lara</last_name>
      <email>fnlara@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>May Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Peggy and Charles Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Homan</last_name>
      <email>sarah-homan@ouhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kiersten During</last_name>
      <email>kiersten-durning@ouhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Raid Aljumaly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Peggy and Charles Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiersten Durning</last_name>
      <email>kiersten-durning@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Raid Aljumaily, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Zigmot</last_name>
      <email>joshua.zigmont@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathrine Senter</last_name>
      <email>Katherine.Senter@jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Takami Sato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Rose</last_name>
      <email>kennaj@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Krystle Eaton</last_name>
      <email>mientkiewiczk@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Diwakar Davar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Whitney Burroughs</last_name>
      <email>whitney.burroughs@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeane Painter</last_name>
      <email>jmgovan@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Ectaerina Dumbrava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <state>City Of London</state>
        <zip>W1G6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Victoria Borja Beral</last_name>
      <email>mariavictoria.borjabernal@hcahealthcare.co.uk</email>
    </contact>
    <contact_backup>
      <last_name>Juan Pedro Navarro Garcia</last_name>
      <email>juanpedro.navarrogarcia@hcahealthcare.co.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Tobias Arkenau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital London</name>
      <address>
        <city>London</city>
        <zip>W1T7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shazia Begum</last_name>
      <email>shazia.begum4@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Heather Shaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Surrey Quays</city>
        <zip>SM25PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan Bar</last_name>
      <email>dan.bar@icr.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Mahesha Ganegoda</last_name>
      <email>mahesha.ganegoda@icr.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Juanita Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

